Abstract: Cabozantinib (XL184) is a potent, orally bioavailable multi-targeted tyrosine kinase inhibitor that has emerged as a critical therapeutic option for advanced hepatocellular carcinoma (HCC). Unlike earlier targeted therapies, cabozantinib uniquely inhibits the vascular endothelial growth factor receptor 2 (VEGFR2) alongside the mesenchymal-epithelial transition factor (MET) and AXL receptor tyrosine kinases. This dual blockade is particularly significant because MET and AXL upregulation are key mechanisms of resistance to prior anti-angiogenic therapies like sorafenib. Based on the pivotal Phase 3 CELESTIAL trial, cabozantinib demonstrated significant improvements in overall survival and progression-free survival in patients with previously treated advanced HCC, leading to its regulatory approval. While its clinical efficacy is robust, the use of cabozantinib is associated with notable adverse events, including palmar-plantar erythrodysesthesia, hypertension, and gastrointestinal toxicities, which require careful management. Furthermore, cost-effectiveness remains a clinical limitation. Current research is heavily focused on the future role of cabozantinib in combination with immune checkpoint inhibitors, such as atezolizumab and nivolumab, to synergistically enhance anti-tumor immunity and overcome resistance in both first-line and subsequent treatment settings.
1. Introduction
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and ranks as the fourth leading cause of cancer-related mortality worldwide [1]. The disease is frequently associated with underlying chronic liver conditions, such as hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, alcohol abuse, and non-alcoholic steatohepatitis [1][4]. Because HCC is often diagnosed at an advanced stage where curative surgical options like resection or liver transplantation are no longer viable, systemic therapy plays a pivotal role in patient management [2][4].
For over a decade, the multi-targeted anti-angiogenic tyrosine kinase inhibitor (TKI) sorafenib was the only approved systemic therapy for advanced HCC [1][2]. However, the landscape of HCC treatment has evolved rapidly, driven by the need to overcome acquired resistance to sorafenib. Cabozantinib (XL184) has emerged as a breakthrough targeted agent. It was approved in Europe (November 2018) and the USA (January 2019) for the treatment of patients with advanced HCC who have previously received sorafenib [1]. By targeting a broader and distinct set of kinase receptors, cabozantinib provides a vital second-line and third-line treatment option for patients progressing on standard therapies.
2. Pharmacological Activity
The clinical pharmacological efficacy of cabozantinib in advanced HCC was definitively established in the global, randomized, double-blind, placebo-controlled Phase 3 CELESTIAL trial (XL184-309) [1][2]. The trial enrolled 707 patients with preserved liver function (Child-Pugh stage A) who had previously received sorafenib and experienced disease progression [1].
In this pivotal study, cabozantinib (60 mg once daily) demonstrated a statistically significant improvement in overall survival (OS) and progression-free survival (PFS). The median OS was 10.2 months for patients treated with cabozantinib compared to 8.0 months for those receiving a placebo (Hazard Ratio [HR] 0.76; p = 0.005) [1][2][3]. Furthermore, the median PFS was significantly extended to 5.2 months versus 1.9 months with placebo (HR 0.44; p < 0.001) [1][4]. The objective response rate (ORR) was 4% in the cabozantinib arm compared to less than 1% in the placebo arm [1].
Subgroup analyses revealed interesting pharmacological nuances based on disease etiology. Cabozantinib appeared particularly potent in patients whose HCC was related to chronic HBV infection, showing an HR for death of 0.69, compared to an HR of 1.11 for patients with HCV-related disease [3][4]. Additionally, health-related quality of life (HRQOL) assessments indicated that while there was a minor initial reduction in quality-adjusted life years (QALYs), continued treatment with cabozantinib led to a clinically and statistically meaningful benefit in mean QALYs over time [1].
3. Molecular Mechanism of Action
Cabozantinib is a potent, orally active multi-targeted tyrosine kinase inhibitor. Its primary mechanism of action involves the simultaneous inhibition of several receptor tyrosine kinases that are critical to tumor angiogenesis, metastasis, and oncogenesis. Specifically, cabozantinib targets VEGFR2 (half maximal inhibitory concentration [IC50] 0.035 nmol/L), the hepatocyte growth factor receptor MET (IC50 1.3 nmol/L), and the AXL receptor tyrosine kinase (IC50 7 nmol/L) [1]. It also exhibits inhibitory activity against other kinases including FLT3 (IC50 11.3 nmol/L), KIT (IC50 4.6 nmol/L), RET (IC50 5.2 nmol/L), TIE-2 (IC50 14.3 nmol/L), and RON (IC50 124 nmol/L) [1][5].
The inclusion of MET and AXL inhibition is the cornerstone of cabozantinib's efficacy in advanced HCC. Both MET and AXL are induced by tumor hypoxia and are heavily implicated in the development of resistance to standard anti-angiogenic therapies like sorafenib [1][3]. The MET/HGF pathway promotes cellular proliferation, survival, and invasion, and increased MET expression serves as a negative prognostic marker in HCC [1]. By providing a dual blockade of VEGFR2 and MET/AXL, cabozantinib effectively suppresses tumor growth and overcomes the acquired resistance mechanisms that typically limit the duration of response to first-line TKIs [3][5].
4. Structure-Activity Relationship (SAR)
While detailed crystallographic SAR mapping is beyond the scope of the provided clinical literature, the structure-activity relationship of cabozantinib is clinically defined by its unique kinase selectivity profile compared to other approved agents like sorafenib, lenvatinib, and regorafenib [1]. The structural conformation of cabozantinib allows it to bind with high affinity to the ATP-binding pockets of not only VEGFR2 but also MET and AXL—targets that are notably absent from the inhibitory profiles of sorafenib and lenvatinib [1].
This specific target affinity translates directly into its clinical utility. For instance, while sorafenib targets VEGFR, PDGFR, and Raf kinases, it lacks activity against MET [3]. Cabozantinib's structural ability to inhibit MET (IC50 1.3 nmol/L) and AXL (IC50 7 nmol/L) at low nanomolar concentrations provides a distinct pharmacological advantage in tumors that have upregulated these pathways to evade VEGFR-only blockade [1]. Furthermore, cabozantinib's broad-spectrum activity against RET and KIT contributes to its ability to inhibit metastasis and tumor angiogenesis across a wide range of preclinical tumor models [1].
5. Current Limitations
Despite its efficacy, the clinical application of cabozantinib is limited by a significant toxicity profile and economic factors. In the CELESTIAL trial, 68% of patients treated with cabozantinib experienced Grade 3 or 4 adverse events (AEs), compared to 36% in the placebo group [1]. The most frequent high-grade AEs included palmar-plantar erythrodysesthesia (PPE) (17%), hypertension (16%), increased aspartate aminotransferase (AST) (12%), fatigue (10%), and diarrhea (10%) [1][2][4]. These toxicities frequently necessitate dose interruptions or reductions (from 60 mg to 40 mg or 20 mg daily), requiring aggressive prophylactic and symptomatic management to maintain patient quality of life [1].
Another major limitation is the drug's cost-effectiveness. Health economic analyses utilizing data from the CELESTIAL trial indicate that at its current cost point, cabozantinib is associated with an incremental cost-effectiveness ratio (ICER) ranging from $156,437 to $1,040,675 per quality-adjusted life-year (QALY) gained (0.067–0.16 QALYs). Consequently, it is currently not considered a cost-effective treatment option for sorafenib-refractory HCC when compared to other second-line agents like regorafenib [5].
Finally, the pivotal trials exclusively enrolled patients with preserved liver function (Child-Pugh stage A). Therefore, the safety and efficacy of cabozantinib in patients with moderately to severely impaired liver function (Child-Pugh B or C), who represent a significant portion of the real-world HCC population, remain largely unknown and limit its broader application [1].
6. Future Perspectives
The future development of cabozantinib in HCC is heavily focused on combination strategies, particularly with immune checkpoint inhibitors (ICIs). Because the toxicity profiles of TKIs and ICIs do not significantly overlap, and because anti-angiogenic agents can reverse the immunosuppressive tumor microenvironment, these combinations hold immense promise [3][4].
Several major clinical trials are currently underway. The Phase 3 COSMIC-312 trial is evaluating the combination of cabozantinib (at a reduced dose of 40 mg) with the anti-PD-L1 antibody atezolizumab versus sorafenib as a first-line systemic therapy for advanced HCC [1][5]. Additionally, the CheckMate040 Phase 1/2 study has reported promising efficacy for cabozantinib combined with nivolumab (median PFS 5.4 months) and a triplet combination of cabozantinib, nivolumab, and ipilimumab (median PFS 6.8 months, median OS not reached) in sorafenib-pretreated patients [1].
Cabozantinib is also being explored in novel clinical settings, such as neoadjuvant therapy prior to definitive resection (CaboNivo trial) and in patients experiencing HCC recurrence after liver transplantation (CaboTx trial) [1]. As the first-line treatment paradigm shifts toward combinations like atezolizumab plus bevacizumab, determining the optimal sequencing of cabozantinib—potentially as a rescue therapy targeting MET-driven resistance post-immunotherapy—will be a critical area of future clinical investigation [1].
